Pfizer puts $1.2 billion medical group up for sale
This article was originally published in Clinica
Pfizer has announced a strategic review of the future of its medical technology group. The group's three units - Howmedica, Schneider Worldwide and American Medical Systems, together have sales of over $1.2 billion. If the sale of the companies goes ahead, it will mean that Pfizer will no longer be represented in the devices industry.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.